A trading pharma manufacturer or wholesaler holds working capital in two pools that move at different speeds: finished and intermediate batch stock sitting in a temperature-controlled store waiting on release, and a sales ledger of invoices to hospitals, pharmacy chains and other licensed wholesalers who pay on terms. Asset-based lending pulls both into one revolving facility, and adds the production and packaging plant where it is worth securing, so the business borrows against the whole regulated supply cycle rather than a single slice of it. The catch specific to this sector is that an appraiser cannot treat a pallet of medicines like a pallet of any other manufactured goods, because the regulation that lets you sell the stock is also the thing that decides how much of it a lender will fund.
What MHRA licensing does to the borrowing base
Eligible inventory in any ABL is valued on what it would raise in an orderly wind-down, not on cost or book value, and the working measure is net orderly liquidation value, the recovery an appraiser stands behind after the cost of selling. In pharma, recovery depends on who is legally allowed to buy the stock and under what authorisation it was made.
Finished medicines can only be sold on by a holder of a Wholesale Dealer's Authorisation, the WDA(H) issued by the Medicines and Healthcare products Regulatory Agency against Good Distribution Practice, with a named Responsible Person standing behind the quality system. Product made under a Manufacturer's or Importer's Authorisation, the MIA, must be certified batch by batch by a Qualified Person before it can be released for sale at all. So an appraiser's first question is not what the stock cost, it is whether a third party with the right MHRA licence could take it on in a default, and whether the batch records and QP certification would survive that buyer's own due diligence. Stock that cannot be cleanly transferred to another licensed holder is stock the lender will not advance against.
This is why an asset-based lending facility for a pharma trader leans on the debtor side more heavily than the headline inventory line suggests. Receivables from licensed, well-rated counterparties are predictable and assignable; batch stock is real collateral but it is discounted hard for the reasons below.
Batch, expiry and the cold chain
Four features push pharmaceutical inventory toward the cautious end of the advance-rate range, and a producer who understands them can argue for a better borrowing base.
- Expiry dating. Every batch carries a finite shelf life and a remaining-dating clause that buyers enforce. A wholesaler will routinely refuse stock with too little life left, often well before the actual expiry. An appraiser models the same thing: a line with eighteen months of dating recovers very differently from the same product with four, so two pallets of identical medicine can carry quite different eligible values purely on remaining shelf life.
- Batch and lot control. Recovery assumes traceable, intact batch documentation. A recall, a quarantine hold, or a gap in the batch record does not just dent one line, it can pull a whole lot out of the eligible pool, because GDP does not let the next holder distribute product whose history is in doubt.
- Cold-chain integrity. Refrigerated and frozen lines are only worth anything if the temperature record is unbroken from manufacture onward. A single logged excursion can write a batch off entirely. Cold-chain stock therefore tends to be advanced against more conservatively, or carved out, unless the monitoring is watertight.
- Controlled-drug status. Schedule 2 to 5 controlled drugs can only be held and moved by a buyer with a Home Office controlled-drugs licence on top of the MHRA authorisation, with the storage, witnessing and record-keeping that entails. That narrows the pool of lawful buyers in a wind-down, so CD lines are valued more cautiously than ordinary prescription stock.
The practical result is that finished, in-date, ambient or well-monitored stock from a strong product with long remaining dating draws a usable advance, while short-dated, recalled, quarantined or CD-heavy lines draw little or nothing. Work in progress, product still inside the manufacturing or release cycle and not yet QP-certified, is generally disregarded altogether, which matters for a manufacturer whose value sits in long batch and stability-testing timelines.
Where the plant and the ledger fit
The production and packaging equipment, the analytical and lab kit, the cold-storage installations, can support a plant-and-machinery tranche inside the facility, and dedicated capital purchases are usually cleaner to fund separately through asset finance on hire purchase or lease, ring-fenced against the asset so the working-capital line stays clear. The debtor book is funded through the invoice finance component, and in pharma the quality of that ledger is unusually high: sales to NHS trusts, large pharmacy multiples and other licensed wholesalers are strong, assignable receivables. Concentration is the live issue, because a wholesaler may run much of its turnover through a handful of accounts, and getting a sensible concentration limit or a named carve-out on a strong counterparty is one of the more valuable moves on a pharma file.
When ABL is the right shape
For a single cold-store, a new blister line or a tablet press, ABL is the wrong tool and asset finance is cleaner. ABL earns its place when working capital is genuinely tied up across both the regulated stock pool and a wholesaler-heavy ledger at the same time, for a business scaling into larger supply contracts, building stock ahead of a tender, or carrying acquired inventory, where debtors, eligible batch stock and plant together create more availability than any one of them alone.
The trade-off is intrusiveness. The facility comes with field audits and periodic inventory appraisals, and availability flexes as expiry dates roll, batches release and stock turns. A business that runs clean batch records, dates and segregates its inventory by remaining shelf life, keeps an unbroken cold-chain log and separates CD lines into their own controlled pool will be advanced more, and audited more cheaply, than one whose system cannot tell in-date ambient finished goods from short-coded refrigerated stock. The discipline GDP already demands is the same discipline that earns a better borrowing base. Set against the wider pharma funding routes, the receivables line, the stock line and the plant tranche read as components of one facility rather than competitors, and the figures worth pressing a lender on are the inventory advance rate by stock category and the concentration treatment of your largest licensed customer.